

# Marta Todeschini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8819476/publications.pdf>

Version: 2024-02-01

39  
papers

3,589  
citations

236612

25  
h-index

301761

39  
g-index

39  
all docs

39  
docs citations

39  
times ranked

4100  
citing authors

#	ARTICLE	IF	CITATIONS
1	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	2.6	20
2	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , 2020, 9, 427-432.	1.6	20
3	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. <i>Frontiers in Medicine</i> , 2020, 7, 579418.	1.2	8
4	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 517-531.	3.0	16
5	Vein Suturing Results in Worse Lung Graft Outcomes Compared to the Cuff Method. <i>European Surgical Research</i> , 2019, 60, 106-116.	0.6	2
6	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 1121-1130.	0.5	14
7	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. <i>JCI Insight</i> , 2019, 4, .	2.3	21
8	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	2.2	58
9	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. <i>American Journal of Transplantation</i> , 2017, 17, 2312-2325.	2.6	32
10	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. <i>Scientific Reports</i> , 2017, 7, 11518.	1.6	89
11	Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts. <i>Stem Cell Reports</i> , 2015, 4, 685-698.	2.3	27
12	Assessment of Anti-donor T Cell Proliferation and Cytotoxic T Lymphocyte-Mediated Lympholysis in Living Donor Kidney Transplant Patients. <i>Methods in Molecular Biology</i> , 2014, 1213, 355-364.	0.4	15
13	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. <i>Age</i> , 2013, 35, 993-1005.	3.0	40
14	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	0.8	148
15	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.4	75
16	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	2.6	151
17	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	2.2	273
18	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. <i>Journal of Immunology</i> , 2011, 186, 4164-4174.	0.4	9

#	ARTICLE	IF	CITATIONS
19	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. <i>Journal of Immunology</i> , 2009, 183, 4249-4260.	0.4	46
20	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. <i>Journal of Immunology</i> , 2008, 181, 3933-3946.	0.4	405
21	Mutations in <i>FN1</i> cause glomerulopathy with fibronectin deposits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2538-2543.	3.3	125
22	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1007-1018.	3.0	224
23	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. <i>Transplantation</i> , 2007, 84, 956-964.	0.5	94
24	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. <i>Thrombosis and Haemostasis</i> , 2005, 93, 443-452.	1.8	81
25	Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature. <i>Blood Purification</i> , 2004, 22, 203-209.	0.9	22
26	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004, 66, 1959-1965.	2.6	52
27	L-Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. <i>Hypertension</i> , 2004, 43, 614-622.	1.3	139
28	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , 2003, 64, 857-863.	2.6	13
29	Familial haemolytic uraemic syndrome and an MCP mutation. <i>Lancet, The</i> , 2003, 362, 1542-1547.	6.3	303
30	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. <i>American Journal of Kidney Diseases</i> , 2002, 40, 783-793.	2.1	66
31	17 $\beta$ -Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 279, F626-F635.	1.3	25
32	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. <i>American Journal of Kidney Diseases</i> , 1999, 33, 746-753.	2.1	42
33	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. <i>American Journal of Kidney Diseases</i> , 1998, 32, 115-124.	2.1	78
34	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. <i>Kidney International</i> , 1997, 52, 171-181.	2.6	138
35	Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. <i>American Journal of Kidney Diseases</i> , 1996, 27, 790-796.	2.1	49
36	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. <i>Circulation Research</i> , 1995, 76, 536-543.	2.0	442

#	ARTICLE	IF	CITATIONS
37	Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. <i>Kidney International</i> , 1993, 44, 445-450.	2.6	204
38	Defective glomerular [ <sup>3</sup> H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. <i>Kidney International</i> , 1993, 44, 747-754.	2.6	1
39	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. <i>Kidney International</i> , 1993, 43, 426-429.	2.6	22